TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02848482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Photodynamic therapy (HELBO Photodynaimc Systems GmbH, Wels, Austria)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical debridement
Description: Plastic scalers (Have implantrecallset, Kerr, Italy) will be used to curette the contaminated sites.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical debridement
Description: Plastic scalers (Have implantrecallset, Kerr, Italy) will be used to curette the contaminated sites.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation
Description: 0.2% chlorhexidine digluconate solution (Bioworld, Madision, US) will be irrigated at contaminated sites for 1 minute.
Study: NCT03489096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoballoon Ablation: PVI + substrate modification
Description: Standard pulmonary vein isolation using cryoballoon ablation, followed by left atrial fibrosis substrate modification using cryoballoon ablation
Study: NCT03950609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given PO
Study: NCT04647799

Intervention type: DEVICE
Intervention: smartphone
Description: Samsung A 71

Intervention type: DEVICE
Intervention: smartphone
Description: Samsung A 71
Study: NCT02067884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced ultrasound imaging
Description: Undergo CEUS
Study: NCT04444648

Intervention type: COMBINATION_PRODUCT
Intervention: No intervention
Description: No intervention
Study: NCT00626366

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sinus CT Scan
Description: Subjects will undergo a Xoran miniCAT scan of their sinuses

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sinus CT Scan
Description: Subjects will undergo a Xoran miniCAT scan of their sinuses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnipaque 240 Contrast Solution
Description: Subjects will spray 2-4 drops of half-strength Omnipaque 240 mgI/mL into each nare. Each spray is approximately 0.1 ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnipaque 240 mg I/mL
Description: Subjects will place two drops of half-strength Omnipaque 240 mg I/mL intranasally to each nose. Each drop is approximately 1 ml.
Study: NCT01191203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copper IUD
Description: Copper IUD (CuT360)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo Medroxyprogesterone acetate
Description: DMPA 150 mg IM q 3 months
Study: NCT04138836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-877
Description: BBT-877 oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-877
Description: BBT-877 oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-877
Description: BBT-877 oral capsule.
Study: NCT02067884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: shear wave elastography
Description: Undergo SWE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity, (Lipid Microspheres) Intravenous Suspension
Description: Participant will receive contrast agent by intravenous administration
Study: NCT04138836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam oral syrup.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole oral capsule.
Study: NCT02067884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips Shear Wave Elastography
Description: Equipment used for SWE
Study: NCT00459342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given orally
Study: NCT01677364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Arm - Induction of labour
Study: NCT02546414

Intervention type: OTHER
Intervention: Platelet count/spleen diameter ratio
Description: Platelet count were evaluated by complete blood count, and ultrasound was used to measure the longest diameter of the spleen.The platelet count/spleen diameter ratio was calculated

Intervention type: OTHER
Intervention: Platelet count/spleen diameter ratio
Description: Platelet count were evaluated by complete blood count, and ultrasound was used to measure the longest diameter of the spleen.The platelet count/spleen diameter ratio was calculated

Intervention type: OTHER
Intervention: Platelet count/spleen diameter ratio
Description: Platelet count were evaluated by complete blood count, and ultrasound was used to measure the longest diameter of the spleen.The platelet count/spleen diameter ratio was calculated
Study: NCT04151784

Intervention type: OTHER
Intervention: Pulmonary Group
Description: Data collection will be obtained on the day an individual has an appointment at the pulmonary clinic. After patients meet with their pulmonary physicians, the physicians will inform them about the study and explain that participation is voluntary. If a patient agrees, the researcher will provide copies of the questionnaires and again clarify that participation is voluntary. The workflow of the clinic will not be interrupted while the researcher conducts the study, and he will only ask participants to fill out the questionnaires if they have enough time to participate.

Intervention type: OTHER
Intervention: Healthy Control
Description: The second group will be recruited as a control group consisting of healthy adult participants through purposive convenience sampling at other collaborating UAB sites. The principal investigator will collect self-report responses through a questionnaire packet given to anyone willing to participate in the study
Study: NCT00846443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent Pemetrexed, Cisplatin and Radiotherapy
Description: pemetrexed:400 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent Pemetrexed, Cisplatin and Radiotherapy
Description: pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent Pemetrexed, Cisplatin and Radiotherapy
Description: pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:70 Gy in 35 fractions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent Pemetrexed, Cisplatin and Radiotherapy
Description: pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:74 Gy in 37 fractions
Study: NCT03681210

Intervention type: DEVICE
Intervention: HeartWare Ventricular Assist Device
Description: The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
Study: NCT01126138

Intervention type: DRUG
Group type: OTHER
Intervention: Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine
Description: Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) Vinorelbine: 25 mg/m2 IV over 3 hours on day 1 and 8, every 3 weeks 21 days as one cycle and 6 cycles are required

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine
Description: Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14), Docetaxel: 75 mg/m2 IV over 3 hours on day 1, every 3 weeks, 21 days as one cycle and 6 cycles are required.~Followed by Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) 21 days as one cycle until progression or unacceptable toxicity
Study: NCT01852201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Mechanical Thrombectomy
Description: Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.
Study: NCT02651155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: Lubiprostone capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lubiprostone placebo-matching capsules
Study: NCT02644720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: multifocal intraocular lens implantation
Description: In this group, the surgery was performed with cataract extraction and multifocal intraocular lens (IOL) (Tecnis ZMB00). The standard technique in all patients consisted of sutureless phacomulsifacation using the Legacy 2000 Series and Infinity phacoemulsification machine (Alcon Laboratories Inc., Fort Worth, Texas, USA), with clear corneal incisions up to 3.2 mm and 5.0 to 5.5 mm capsulorhexis. Surgery in the fellow eye was performed 1 month later in each patient.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: monofocal intraocular lens implantation
Description: In the group, the surgery was performed with cataract extraction and monofocal intraocular lens (IOL) (Tecnis ZCB). The surgery technique was same as the multifocal intraocular lens group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: All patients received subconjunctival dexamethasone (2 mg) during surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: All patients received subconjunctival dexamethasone (2 mg) during surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multifocal intraocular lens (IOL) (Tecnis ZMB00)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: monofocal intraocular lens (IOL) (Tecnis ZCB)
Study: NCT01754961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D 500,000 IU given orally on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given orally on Day 1
Study: NCT01713114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute measures of satiety and food intake at next meal
Study: NCT04413591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community based combination HIV prevention package
Description: The intervention compares the efficacy of a community-based comprehensive HIV/STI prevention package compared to standard of care (HIV testing, counseling, and referrals) among Female Sex Workers.
Study: NCT00317499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept
Study: NCT02133339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRN-157

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03305055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: Information included in arm descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Information included in arm descriptions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Information included in arm descriptions
Study: NCT04488640

Intervention type: PROCEDURE
Intervention: Thyroid biopsy with ultrasound
Description: Patients with thyroid nodules who underwent ultrasound-guided core needle biopsy with a 20 gauge core needle biopsy apparatus were included in the study.

Intervention type: PROCEDURE
Intervention: Thyroid biopsy with ultrasound
Description: Patients with thyroid nodules who underwent ultrasound-guided core needle biopsy with a 20 gauge core needle biopsy apparatus were included in the study.
Study: NCT04473508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local administration of ropivacaine
Description: Erector nerve block with local ropivacaine injection in addition with conventional anesthesia for spine surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Local administration of placebo (saline solution)
Description: injection of saline solution in addition with conventional anesthesia for spine surgery
Study: NCT04552704

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc
Description: Given IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given IV
Study: NCT03497533

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TriCAR-T-CD19
Description: A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 0.5-1 x 10\^6 CAR+ T cells/kg
Study: NCT01903486

Intervention type: DRUG
Group type: OTHER
Intervention: Apo-Prednisone Cordorol, Detasone - Prednisone
Description: Oral prednisone (study medication) at a dose of 40mg for 1 week, then 30mg for 1 week, then 20mg for 1 week, then 10mg for 1 week, and then stop the medication.
Study: NCT02352883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo mastectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Surgical Procedure
Description: Undergo wide local excision

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy
Description: Undergo endocrine therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy
Description: Undergo endocrine therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study: NCT04809870

Intervention type: PROCEDURE
Intervention: surgery
Description: retrospective comparison of esophagectomy for esophageal cancer in patients with or without concomitant liver cirrhosis

Intervention type: PROCEDURE
Intervention: surgery
Description: retrospective comparison of esophagectomy for esophageal cancer in patients with or without concomitant liver cirrhosis
Study: NCT02044627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C-ETC-1002]
Study: NCT04215016

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells
Description: Humanized anti-CD19 and CD20 bispecific autologous CAR-T cells injection: the first dose is 1.0×106 /kg, the second dose is 3.0×106 /kg, and the third dose is 8.0×106 /kg. Patients will receive lymphodepleting chemotherapy at least 1 week before CAR-T cell infusion.
Study: NCT01712009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Study: NCT01713114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute measures of satiety and food intake at next meal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acute measures of satiety and food intake at next meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute measures of satiety and food intake at next meal
Study: NCT01651416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin Piperaquine combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine plus sulphadoxine-pyrimethamine combination
Study: NCT03779126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: 1) Low frequency electrical stimulation (LF) ; High frequency (HF); Low and High frequency (LHF) ; and sham stimulation. Groups will receive bilaterally electrical stimulation, for 60 minutes, three times a week, during two months.
Study: NCT01872065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03000426

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free gingival graft
Description: Free gingival graft removal from palate for socket preservation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free gingival graft
Description: Free gingival graft removal from palate for socket preservation

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Free gingival graft
Description: Free gingival graft removal from palate for socket preservation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GaAlAs laser
Description: Utilization of GaAlAs laser to irradiation on the palatal donor site for photobiomodulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GaAlAs laser
Description: Utilization of GaAlAs laser to irradiation on the palatal donor site for photobiomodulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GaAlAs laser
Description: Utilization of GaAlAs laser to irradiation on the palatal donor site for photobiomodulation
Study: NCT01940887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E10030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab or aflibercept
Description: Patients are randomized to receive either bevacizumab or aflibercept
Study: NCT01712009

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pegfilgrastim
Description: Commercially available pegfilgrastim (Neulasta®) will be used in the study, and is considered background therapy. Pegfilgrastim is administered as a single 6 mg subcutaneous injection 24 hours to 72 hours after completion of chemotherapy.
Study: NCT01940887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab or aflibercept
Description: Patients are randomized to receive either bevacizumab or aflibercept

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E10030 sham injection
Description: Pressure on the eye with a syringe with no needle
Study: NCT03104439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: The antibodies in nivolumab work by causing programmed cell death of the cancer cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: The antibodies in ipilimumab work by not allowing cancer cell growth

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy is believed to increase the likelihood of response of immunotherapy
Study: NCT04109820

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MitoQ
Description: Oral; 20mg once a day for 14 days
Study: NCT01712009

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Commercially available pegfilgrastim (Neulasta®) will be used in the study, and is considered background therapy. Pegfilgrastim is administered as a single 6 mg subcutaneous injection 24 hours to 72 hours after completion of chemotherapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Commercially available pegfilgrastim (Neulasta®) will be used in the study, and is considered background therapy. Pegfilgrastim is administered as a single 6 mg subcutaneous injection 24 hours to 72 hours after completion of chemotherapy.
Study: NCT04109820

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: Oral; 20mg once a day for 14 days
Study: NCT01712009

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy
Description: The choice of chemotherapy regimen (agent, dose, and schedule) is at the discretion of the treating physician.
Study: NCT01270464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: 3.0 mg/kg or 0.3 mg/kg doses administered intravenously (iv) by qualified site personnel once every 4 weeks, for a total of 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: 3.0 mg/kg or 0.3 mg/kg doses administered intravenously (iv) by qualified site personnel once every 4 weeks, for a total of 4 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by iv infusion by qualified study personnel every 4 weeks for a total of 4 doses.
Study: NCT00511082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-31121
Description: Patients will receive OPB-31121 administered orally, once daily for 4 weeks.